WebApr 10, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they expect the company's stock price to reach $25.83 in the next year. This suggests a possible upside of 175.4% from the stock's current price. WebSee what employees say it's like to work at Dyne Therapeutics. Salaries, reviews, and more - all posted by employees working at Dyne Therapeutics.
Dyne Therapeutics Presents New In Vivo Data from DYNE-101
WebSep 1, 2024 · Dyne Therapeutics: ClinicalTrials.gov Identifier: NCT05524883 Other Study ID Numbers: DYNE251-DMD-201 2024-005478-24 ( EudraCT Number ) First Posted: September 1, 2024 Key Record Dates: Last Update Posted: March 27, 2024 Last Verified: March 2024 Individual Participant Data (IPD) Sharing Statement: ... WebApr 3, 2024 · To solve that problem, a startup called Dyne Therapeutics has raised $50 million in series A financing to develop antibody-oligo conjugates that shuttle oligo therapies into muscle cells. how fast is cat5e
Dyne Therapeutics Career: Working at Dyne Therapeutics …
WebDec 11, 2024 · Dyne Therapeutics will lease 68,187 square feet at 1560 Trapelo Road in Waltham. Dyne Therapeutics. By Catherine Carlock – Real Estate Editor, Boston Business Journal. Dec 11, 2024. WebJan 10, 2024 · WALTHAM, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living ... WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … high end logo wear